Combining transcriptomic and metabolomic insights to guide the clinical application of adipose- and bone marrow-derived mesenchymal stem cells-Reference-Cited by-同舟云学术

Combining transcriptomic and metabolomic insights to guide the clinical application of adipose- and bone marrow-derived mesenchymal stem cells

Published:2024-08-29 Issue: Volume: Page:
ISSN:2749-9642
Container-title:Medical Review
language:en
Short-container-title:

Author:

Zhou Wenyan¹²,Lin Junxin¹,Hay David C.³,Yao Xudong⁴,Ouyang Hongwei²⁵⁶^ORCID

Affiliation:

1. School of Medicine , Taizhou University , Taizhou , Zhejiang , China

2. Dr. Li Dak Sum & Yip Yio Chin Center for Stem Cells and Regenerative Medicine , 12377 Zhejiang University School of Medicine , Hangzhou , Zhejiang , China

3. Centre for Regenerative Medicine, Institute for Regeneration and Repair , University of Edinburgh , Edinburgh , UK

4. International School of Medicine, International Institutes of Medicine , 12377 The Fourth Affiliated Hospital of Zhejiang University School of Medicine , Yiwu , Zhejiang , China

5. Department of Sports Medicine of the Second Affiliated Hospital, and Liangzhu Laboratory , 12377 Zhejiang University School of Medicine , Hangzhou , China

6. China Orthopedic Regenerative Medicine Group (CORMed) , Hangzhou , China

Abstract

Abstract Adipose-derived mesenchymal stem cells (ADSCs) and bone marrow-derived mesenchymal stem cells (BMSCs) have shown great potential in clinical applications. However, the similarities and differences between these two cell types have not been fully elucidated. Recent advances in transcriptomic and metabolomic research have provided valuable insight into the characteristics and functions of ADSCs and BMSCs. In this perspective article, we review the key findings from these studies, including cellular heterogeneity as well as differences in metabolic and secretory properties. We discuss how these insights can help guide the selection of the most suitable cell source for the clinic, and the optimization of preconditioning strategies prior to clinical deployment. Furthermore, we analyze the current landscape of products and clinical trials involving ADSCs and BMSCs, highlighting their therapeutic potential. We propose that the integration of multi-omics datasets will be crucial for establishing a comprehensive understanding of ADSC and BMSC identity and potency, and the provision of quality-assured stem cell-derived products for the clinic.

Funder

National Natural Science Foundation of China

Publisher

Walter de Gruyter GmbH

Link

https://www.degruyter.com/document/doi/10.1515/mr-2024-0056/pdf

Reference33 articles.

1. Zhou, W, Lin, J, Zhao, K, Jin, K, He, Q, Hu, Y, et al.. Single-cell profiles and clinically useful properties of human mesenchymal stem cells of adipose and bone marrow origin. Am J Sports Med 2019;47:1722–33. https://doi.org/10.1177/0363546519848678.

2. Hou, W, Duan, L, Huang, C, Li, X, Xu, X, Qin, P, et al.. Cross-tissue characterization of heterogeneities of mesenchymal stem cells and their differentiation potentials. Front Cell Dev Biol 2021;9:781021. https://doi.org/10.3389/fcell.2021.781021.

3. Wang, Z, Chai, C, Wang, R, Feng, Y, Huang, L, Zhang, Y, et al.. Single-cell transcriptome atlas of human mesenchymal stem cells exploring cellular heterogeneity. Clin Transl Med 2021;11:e650. https://doi.org/10.1002/ctm2.650.

4. Merrick, D, Sakers, A, Irgebay, Z, Okada, C, Calvert, C, Morley, MP, et al.. Identification of a mesenchymal progenitor cell hierarchy in adipose tissue. Science. 2019;364. https://doi.org/10.1126/science.aav2501.

5. Vijay, J, Gauthier, MF, Biswell, RL, Louiselle, DA, Johnston, JJ, Cheung, WA, et al.. Single-cell analysis of human adipose tissue identifies depot and disease specific cell types. Nat Metab 2020;2:97–109. https://doi.org/10.1038/s42255-019-0152-6.